The speculation around the elephant in the room is finally resolved. Its not an elephant, it is in fact a lion. Many thanks to Hottod for her diligent note taking during the Investor Call that provided some of the answers although the final reveal came with a surprise. We are now officially a DIY biotech thanks to the strategic partnership with the Lions Eye Institute and courtesy of our Chief of Research and Development.
PYC has transitioned from a delivery platform to an Antisense Oligonucleotide platform with global expertise in the design and delivery of RNA therapeutics from bench to bedside. Talk about a quantum leap. One cannot but marvel at the achievement. Decades of research at the leading edge of medical science coalescing into PYC and the collaborative vehicle, Vision Pharma. Its the beginning of quite an adventure.
In all the excitement, I need to remind myself that we have selected a lead drug candidate.
PYC Price at posting:
4.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)